188 studies found for:    • Immunodeficiency NOT (AIDS OR Stem Cell)
Show Display Options
Rank Status Study
21 Recruiting Gamma Globulin Observations and Outcomes Database for Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI)
Condition: Primary Immune Deficiency Disorder
Intervention: Other: Immunoglobulin Therapy
22 Completed Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1
Conditions: Growth Failure;   X-linked Severe Combined Immunodeficiency (XSCID);   Growth Hormone Resistence
Interventions: Drug: Increlex;   Procedure: Arginine Provocation Test;   Procedure: Clonidine Provocation Test;   Procedure: IGF-1 Generation Test;   Drug: IVIG;   Procedure: Haplo-Identical Bone Marrow Transplant
23 Recruiting Genetic Basis of Primary Immunodeficiencies
Condition: Immunologic Deficiency Syndrome
Intervention:
24 Unknown  Randomized Study of Polyethylene-Glycol-Conjugated Interleukin 2 in Patients With Common Variable Immunodeficiency
Condition: Common Variable Immunodeficiency
Intervention: Drug: PEG-interleukin-2
25 Completed
Has Results
Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
Conditions: Agammaglobulinemia;   IgG Deficiency;   Common Variable Immunodeficiency
Intervention: Drug: Immunoglobulins Intravenous (Human)
26 Recruiting Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Conditions: Primary Immune Deficiency Disorders;   Common Variable Immunodeficiency;   X-linked Agammaglobulinaemia;   Hyper-IgM Syndrome
Interventions: Biological: Gammaplex (5%);   Biological: Gammaplex 10
27 Completed
Has Results
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
Condition: Primary Immunodeficiency (PID)
Intervention: Drug: Immune Globulin Intravenous (Human), 10%
28 Active, not recruiting Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)
Condition: Primary Immunodeficiency Disorders
Intervention: Biological: RI-002
29 Completed Tolerability and Safety of Immune Globulin Subcutaneous Solution and rHuPH20 in Primary Immunodeficiency Diseases (PID)
Condition: Primary Immunodeficiency Diseases (PID)
Intervention: Biological: Immune Globulin Subcutaneous Solution (IGSC)
30 Completed Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population
Conditions: Severe Combined Immunodeficiency;   T Cell Lymphocytopenia
Intervention:
31 Completed Study of Vitamin D3 Substitution to Patients With Primary Immunodeficiency
Condition: Primary Immune Deficiency Disorder
Interventions: Drug: Vigantol;   Drug: Placebo
32 Recruiting Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
Condition: Primary Immunodeficiency Disease (PIDD)
Intervention:
33 Unknown  Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1)
Condition: X-linked Severe Combined Immunodeficiency
Intervention: Genetic: Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
34 Completed Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency
Condition: Immunologic Deficiency Syndrome
Intervention: Drug: Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™
35 Terminated Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases
Condition: Immunologic Deficiency Syndromes
Intervention: Drug: Octagam 10%
36 Active, not recruiting Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)
Condition: Primary Immune Deficiency
Intervention: Biological: Immune globulin subcutaneous (Human)
37 Completed Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study
Condition: Severe Combined Immunodeficiency
Interventions: Drug: ADA PBSC;   Drug: ADA Umbilical Cord Blood Cells;   Drug: Transduced Lymphocytes
38 Terminated Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States
Conditions: Hyper-IgM Syndrome;   Ectodermal Dysplasia
Intervention:
39 Completed
Has Results
Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)
Condition: Primary Immune Deficiency Disorders (PIDD)
Intervention: Biological: Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]
40 Recruiting Assessment of Immunoglobulins (IgG) in a Long-term Non-interventional Study
Conditions: Primary Immunodeficiency (PID);   Secondary Immunodeficiency (SID);   Neurological Autoimmune Disease
Intervention: Other: Immunoglobulin G (IgG)

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years